Polymer based cardiovascular gene therapy

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Therapeutic angiogenesis is a new potential treatment in cardiovascular disease. It is performed by the delivery of the angiogenic agents (protein, gene). Most important consideration for gene therapy is the construction of an effective therapeutic gene. Currently, VEGF is the most effective therapeutic gene for the neovascularization. We constructed the hypoxia-regulated VEGF plasmid using the Epo enhancer and RTP801 promoter. The efficiency of the pEpo-SV-VEGF and pRTP801-VEGF were evaluated by various methods in vitro and in vivo. The results suggested that the hypoxia-inducible VEGF gene therapy system is effective and safe, which may be useful for the gene therapy of ischemic heart disease. Development of a safe and efficient gene carrier is another main requirement for successful gene therapy. Although viral-based gene delivery is currently the most effective way to transfer genes to cells, nonviral vectors are increasingly being considered for in vivo gene delivery. The advantages of nonviral gene therapy are lack of specific immunogenecity, simplicity of use, and ease of large-scale production. In addition, the simple conjugation of a targeting moiety to nonviral gene carrier can facilitate tissue-targeting gene delivery. We have developed two new gene carrier systems, TerplexDNA and WSLP (water soluble lipopolymer). These two are efficient carrier to ischemic myocardium and has low toxicity and high transfection efficiency. So it may allow for application of in vivo gene therapy in the treatment of heart disease.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalBiotechnology and Bioprocess Engineering
Volume12
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Gene therapy
Genetic Therapy
Polymers
Genes
Vascular Endothelial Growth Factor A
Angiogenic Proteins
Gene transfer
Therapeutics
Gene Targeting
Viral Genes
Myocardial Ischemia
Transfection
Toxicity
Heart Diseases
Myocardium
Plasmids
Cardiovascular Diseases
Tissue
Proteins

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering

Cite this

@article{ba5c096133074e1294ccb48faf0345f9,
title = "Polymer based cardiovascular gene therapy",
abstract = "Therapeutic angiogenesis is a new potential treatment in cardiovascular disease. It is performed by the delivery of the angiogenic agents (protein, gene). Most important consideration for gene therapy is the construction of an effective therapeutic gene. Currently, VEGF is the most effective therapeutic gene for the neovascularization. We constructed the hypoxia-regulated VEGF plasmid using the Epo enhancer and RTP801 promoter. The efficiency of the pEpo-SV-VEGF and pRTP801-VEGF were evaluated by various methods in vitro and in vivo. The results suggested that the hypoxia-inducible VEGF gene therapy system is effective and safe, which may be useful for the gene therapy of ischemic heart disease. Development of a safe and efficient gene carrier is another main requirement for successful gene therapy. Although viral-based gene delivery is currently the most effective way to transfer genes to cells, nonviral vectors are increasingly being considered for in vivo gene delivery. The advantages of nonviral gene therapy are lack of specific immunogenecity, simplicity of use, and ease of large-scale production. In addition, the simple conjugation of a targeting moiety to nonviral gene carrier can facilitate tissue-targeting gene delivery. We have developed two new gene carrier systems, TerplexDNA and WSLP (water soluble lipopolymer). These two are efficient carrier to ischemic myocardium and has low toxicity and high transfection efficiency. So it may allow for application of in vivo gene therapy in the treatment of heart disease.",
author = "Donghoon Choi",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/BF02931801",
language = "English",
volume = "12",
pages = "39--42",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "1",

}

Polymer based cardiovascular gene therapy. / Choi, Donghoon.

In: Biotechnology and Bioprocess Engineering, Vol. 12, No. 1, 01.01.2007, p. 39-42.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Polymer based cardiovascular gene therapy

AU - Choi, Donghoon

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Therapeutic angiogenesis is a new potential treatment in cardiovascular disease. It is performed by the delivery of the angiogenic agents (protein, gene). Most important consideration for gene therapy is the construction of an effective therapeutic gene. Currently, VEGF is the most effective therapeutic gene for the neovascularization. We constructed the hypoxia-regulated VEGF plasmid using the Epo enhancer and RTP801 promoter. The efficiency of the pEpo-SV-VEGF and pRTP801-VEGF were evaluated by various methods in vitro and in vivo. The results suggested that the hypoxia-inducible VEGF gene therapy system is effective and safe, which may be useful for the gene therapy of ischemic heart disease. Development of a safe and efficient gene carrier is another main requirement for successful gene therapy. Although viral-based gene delivery is currently the most effective way to transfer genes to cells, nonviral vectors are increasingly being considered for in vivo gene delivery. The advantages of nonviral gene therapy are lack of specific immunogenecity, simplicity of use, and ease of large-scale production. In addition, the simple conjugation of a targeting moiety to nonviral gene carrier can facilitate tissue-targeting gene delivery. We have developed two new gene carrier systems, TerplexDNA and WSLP (water soluble lipopolymer). These two are efficient carrier to ischemic myocardium and has low toxicity and high transfection efficiency. So it may allow for application of in vivo gene therapy in the treatment of heart disease.

AB - Therapeutic angiogenesis is a new potential treatment in cardiovascular disease. It is performed by the delivery of the angiogenic agents (protein, gene). Most important consideration for gene therapy is the construction of an effective therapeutic gene. Currently, VEGF is the most effective therapeutic gene for the neovascularization. We constructed the hypoxia-regulated VEGF plasmid using the Epo enhancer and RTP801 promoter. The efficiency of the pEpo-SV-VEGF and pRTP801-VEGF were evaluated by various methods in vitro and in vivo. The results suggested that the hypoxia-inducible VEGF gene therapy system is effective and safe, which may be useful for the gene therapy of ischemic heart disease. Development of a safe and efficient gene carrier is another main requirement for successful gene therapy. Although viral-based gene delivery is currently the most effective way to transfer genes to cells, nonviral vectors are increasingly being considered for in vivo gene delivery. The advantages of nonviral gene therapy are lack of specific immunogenecity, simplicity of use, and ease of large-scale production. In addition, the simple conjugation of a targeting moiety to nonviral gene carrier can facilitate tissue-targeting gene delivery. We have developed two new gene carrier systems, TerplexDNA and WSLP (water soluble lipopolymer). These two are efficient carrier to ischemic myocardium and has low toxicity and high transfection efficiency. So it may allow for application of in vivo gene therapy in the treatment of heart disease.

UR - http://www.scopus.com/inward/record.url?scp=33847782616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847782616&partnerID=8YFLogxK

U2 - 10.1007/BF02931801

DO - 10.1007/BF02931801

M3 - Review article

AN - SCOPUS:33847782616

VL - 12

SP - 39

EP - 42

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 1

ER -